Laura S Graham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9274642/publications.pdf

Version: 2024-02-01

1478505 1588992 12 151 8 6 citations h-index g-index papers 12 12 12 307 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	3.9	15
2	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts) Journal of Clinical Oncology, 2022, 40, 138-138.	1.6	0
3	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes Journal of Clinical Oncology, 2022, 40, 129-129.	1.6	0
4	Inherited germline variants in urothelial cancer: A multicenter whole-exome sequencing analysis Journal of Clinical Oncology, 2022, 40, 451-451.	1.6	0
5	Mismatch repair deficiency and clinical implications in prostate cancer. Prostate, 2022, 82, .	2.3	9
6	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation, 2021, 39, 21-24.	1.3	1
7	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in highâ€risk localized prostate cancer. Prostate, 2021, 81, 418-426.	2.3	8
8	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. Clinical Cancer Research, 2021, 27, 6662-6665.	7.0	11
9	Multimodality Treatment of Bilateral Wilms Tumor in a Pregnant Female. Urology, 2020, 136, e42-e44.	1.0	0
10	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS ONE, 2020, 15, e0233260.	2.5	63
11	Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review. Clinical Genitourinary Cancer, 2018, 16, e335-e338.	1.9	4
12	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Medical Oncology, 2016, 33, 44.	2.5	40